Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin

Journal of Molecular Recognition

Volumn 24, Issue 6, 2011, Pages 1043-1055

  Santini, Simona ^a   Bizzarri, Anna Rita ^a   Cannistraro, Salvatore ^a  

^a UNIVERSITY OF TUSCIA   (Italy)

Author keywords

docking; free energy; molecular dynamics; p28; p53

Indexed keywords

ANTINEOPLASTIC AGENT; AZURIN; AZURIN (50 77); AZURIN (50-77); PEPTIDE FRAGMENT; PROTEIN P53;

ARTICLE; CHEMICAL MODEL; CHEMISTRY; MOLECULAR DYNAMICS; PROTEIN TERTIARY STRUCTURE;

ANTINEOPLASTIC AGENTS; AZURIN; MODELS, CHEMICAL; MOLECULAR DYNAMICS SIMULATION; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80155152620     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.1153     Document Type: Article

References (63)

1. Andricioaei I, Karplus M,. 2001. On the calculation of entropy from covariance matrices of the atomic fluctuations. J. Chem. Phys. 115: 6289-6292.
2. Apiyo D, Wittung-Stafshede P,. 2005. Unique complex between bacterial Azurin and tumor-suppressor protein p53. Biochem. Biophys. Res. Commun. 332: 965-968. (Pubitemid 40798181)
3. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA,. 2001. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98: 010037-10041.
4. Basdevant N, Weinstein H, Ceruso M,. 2006. Thermodynamic Basis for Promiscuity and Selectivity in Protein-Protein Interactions: PDZ Domains, a Case Study. J. Am. Chem. Soc. 128: 12766-12777. (Pubitemid 44527753)
5. Berendsen HJC, Postma JPM, Van Gunsteren WF, Hermans J,. 1969. Interaction models for water in relation to protein hydration. Nature 224: 175-177.
6. Bizzarri AR, Di Agostino S, Andolfi L, Cannistraro S,. 2009. A Combined Atomic Force Microscopy Imaging and Docking Study to Investigate the Complex Between p53 DNA Binding Domain and Azurin. J. Mol. Recognit. 22: 506-15.
7. Brooks CL, Gu W,. 2006. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21: 307-315. (Pubitemid 43163526)
8. Chan WM, Mak MC, Fung TK, Lau A, Siu WY, Poon RYC,. 2006. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol. Cancer Res. 4: 15-25. (Pubitemid 43259886)
9. Chen R, Weng Z,. 2002. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins: Struct. Funct. Genet. 47: 281-294. (Pubitemid 34438678)
10. Chen R, Weng Z,. 2003. A novel shape complementarity scoring function for protein-protein docking. Proteins: Struct. Funct. Genet. 51: 397-408. (Pubitemid 36528825)
11. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W,. 2005. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121: 1071-1083. (Pubitemid 40884397)
12. Cho Y, Gorina S, Jeffrey PD, Pavletich NP,. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355. (Pubitemid 24259959)
13. Clegg HV, Itahana K, Zhang Y,. 2008. Unlocking the M dm2-p53 loop: Ubiquitin is the key. Cell Cycle 7: 287-292. (Pubitemid 351366489)
14. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM,. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265: 386-391. (Pubitemid 24259970)
15. Comeau SR, Gatchell DW, Vajda S, Camacho CJ,. 2004. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 32: 96-99.
16. Corcoran C, Huang Y, Sheikh M,. 2004. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest. Cancer Biol. Ther. 3: 721-725. (Pubitemid 41351074)
17. Chong LT, Duan Y, Wang L, Massova I, Kollman PA,. 1999. Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc. Natl. Acad. Sci. USA 96: 14330-14335. (Pubitemid 30000650)
18. DeLano WL,. 2002. The PyMOL molecular graphics system.
19. De Grandis V, Bizzarri AR, Cannistraro S,. 2007. Docking study and free energy simulation of the complex between p53 DNA-binding domain and Azurin. J. Mol. Recognit. 20: 215-226. (Pubitemid 47523028)
20. Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, French DM,. 2004. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 64: 7226-7230. (Pubitemid 39372056)
21. + on DNA recognition and stability of the p53 DNA-binding domain. Biochemistry 45: 7483-7492. (Pubitemid 43894942)
22. Espinoza-Fonseca LM,. 2005. Targeting MDM2 by the small molecule RITA: Towards the development of new multi-target drugs against cancer. Theor. Biol. Medical Modelling 2.
23. Ganoth A, Friedman R, Nachliel E, Gutman M,. 2006. A molecular dynamics study and free energy analysis of complexes between the Mlc1p protein and two IQ motif peptides. Biophys. J. 91: 2436-2450. (Pubitemid 44511700)
24. Goto M, Yamada T, Kimbara K, Horner J, Newcomb M, Das Gupta TK, Chakrabarty AM,. 2003. Induction of apoptosis in macrophages by Pseudomonas Aeruginosa Azurin: tumour-suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxicity. Mol. Microbiol. 47: 549-559. (Pubitemid 36121043)
25. Greenblatt MS, Bennett WP, Hollstein M, Harris CC,. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878. (Pubitemid 24289415)
26. Harris CC,. 1996. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88: 1442-1455. (Pubitemid 26340046)
27. Haupt Y, Maya R, Kazaz A, Oren M,. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. (Pubitemid 27220766)
28. Hess B, Kutzner C, Van der Spoel D, Lindahl E,. 2008. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theor. Comput. 4: 435-447.
29. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM,. 1997. LINCS: a linear constraint solver for molecular simulations. J. Comp. Chem. 18: 1463-1472. (Pubitemid 127637344)
30. Jeffrey PD, Gorina S, Pavletich NP,. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267: 1498-1502.
31. Jones S, Thornton JM,. 1996. Principles of protein-protein interactions derived from structural studies. Proc Natl Acad Sci USA 93: 13-20. (Pubitemid 26038096)
32. Klein C, Vassilev LT,. 2004. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91: 1415-9. (Pubitemid 39486340)
33. Klein C, Planker E, Diercks T, Kessler H, Kunkele KP, Lang K, Hansen S, Schwaiger M,. 2001. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J. Biol. Chem. 276: 49020-49027.
34. Lane DP,. 1992. Cancer. p53, guardian of the genome. Nature 358: 15-16.
35. Levine AJ,. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331. (Pubitemid 27131374)
36. Lindberg M, Gräslund A,. 2001. The position of the cell penetrating peptide penetration in SDS micelles determined by NMR. FEBS Lett. 497: 39-44. (Pubitemid 32480177)
37. Lundberg P, Langel Ü,. 2003. A brief introduction to cell-penetrating peptides. J. Mol. Recogn. 16: 227-233. (Pubitemid 37231690)
38. Magzoub M, Eriksson LE, Gräslund A,. 2003. Comparison of the interaction, positioning, structure induction and membrane perturbation of cell-penetrating peptides and non-translocating variants with phospholipid vesicles. Biophys. Chem. 103: 271-288. (Pubitemid 36506473)
39. Massova I, Kollman PA,. 1999. Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J. Am. Chem. Soc. 121: 8133-8143. (Pubitemid 29444447)
40. Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, Das Gupta TK,. 2010. A 28-amino-acid peptide fragment of the cupredoxin Azurin prevents carcinogen-induced mouse mammary lesions. Cancer Prev Res 3: 1351-1360.
41. Nar H, Messerschmidt A, Huber R, van de Kamp M, Canters GW,. 1991. Crystal structure analysis of oxidized Pseudomonas aeruginosa Azurin at pH 5.5 and pH 9.0. A pH-induced conformational transition involves a peptide bond flip. J. Mol. Biol. 221: 765-772. (Pubitemid 121003417)
42. Nooren IMA, Thornton JM,. 2003. Structural characterization and functional significance of transient protein-protein interactions. J. Mol. Biol. 325: 991-1018. (Pubitemid 36263408)
43. Nose' S,. 1984. A molecular dynamics method for simulations in the canonical ensemble. Mol. Phys. 52: 255-268.
44. Oren M,. 2003. Decision making by p53: life, death and cancer. Cell Death Diff. 10: 431-442. (Pubitemid 36626355)
45. Parrinello M, Rahman A,. 1981. Polymorphic transitions in single crystals: a new molecular dynamics method. J. Appl. Phys. 52: 7182-7190. (Pubitemid 12456820)
46. Punj V, Das Gupta TK, Chakrabarty AM,. 2003. Bacterial cupredoxin Azurin and its interactions with the tumor suppressor protein p53. Biochem. Biophys. 312: 109-114. (Pubitemid 37443934)
47. Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, Yamada T, Constantinou AI, Christov K, White B, Li G, Majumdar D, Chakrabarty AM, Das Gupta TK,. 2004. Bacterial cupredoxin Azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 23: 2367-2378. (Pubitemid 38496792)
48. Rajendra R, Malegaonkar D, Pungaliya P, Marshall H, Rasheed Z, Brownell J, Liu LF, Lutzker S, Saleem A, Rubin EH,. 2004. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J. Biol. Chem. 279: 36440-36444. (Pubitemid 39128984)
49. Seeliger D, De Groot BL,. 2010. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 24: 417-422.
50. Srinivasan J, Cheatham TE, Cieplak P, Kollman PA, Case DA,. 1998. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J. Am. Chem. Soc. 120: 9401-9409. (Pubitemid 28452628)
51. Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, Das Gupta TK,. 2009. Noncationic peptides obtained from Azurin preferentially enter cancer cells. Cancer Res. 69: 537-546.
52. Taranta M, Bizzarri AR, Cannistraro S,. 2008. Probing the interaction between p53 and the bacterial protein Azurin by single molecule force spectroscopy. J. Mol. Recognit. 21: 63-70. (Pubitemid 351300460)
53. Taranta M, Bizzarri AR, Cannistraro S,. 2009. Modelling the interaction between the N-terminal domain of the tumor suppressor p53 and Azurin. J. Mol. Recognit. 22: 215-222.
54. Van der Spoel D, van Buuren AR, Apol E, Meulenhoff PJ, Tieleman DP, Sijbers A, Hess B, Feenstra KA, Lindahl E, van Drunen R, Berendsen HJC,. 2001. GROMACS User Manual. University of Groningen: Groningen, The Netherlands, Version 3.2.
55. Vassilev LT,. 2004. Small-molecule inhibitors of p53-MDM2 binding: research tools and potential cancer therapeutics. Cell Cycle 3: 419-421. (Pubitemid 40278226)
56. Veprintsev DB, Freund SMV, Andreeva A, Rutledge SE, Tidow H, Pérez Canëadillas JM, Blair CM, Fersht AR,. 2006. Core domain interactions in full-length p53 in solution. Proc. Natl. Acad. Sci. USA 103: 2115-2119. (Pubitemid 43271632)
57. Vogelstein B, Lane D, Levine AJ,. 2000. Surfing the p53 network. Nature 408: 307-310.
58. Wu Y, Cao Z, Yi H, Jiang D, Mao X, Liu H, Li W,. 2004. Simulation of the interaction between ScyTx and small conductance calcium-activated potassium channel by docking and MM-PBSA. Biophys. J. 87: 105-112. (Pubitemid 38880069)
59. Yamada T, Fialho AM, Punj V, Bratescu L, Das Gupta TK, Chakrabarty AM,. 2005. Internalization of bacterial redox protein Azurin in mammalian cells: entry domain and specificity. Cell Microb. 10: 1418-1431. (Pubitemid 41335246)
60. Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, Majumdar D, Cunningham E, Das Gupta TK, Chakrabarty AM,. 2002a. Bacterial redox protein Azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. USA 99: 14098-14103. (Pubitemid 35257631)
61. Yamada T, Goto M, Punj V, Zaborina O, Kimbara K, Das Gupta TK, Chakrabarty AM,. 2002b. The bacterial redox protein Azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53. Infect. Immun. 70: 7054-7062. (Pubitemid 35387942)
62. Yamada T, Hiraoka Y, Ikehata M, Kimbara K, Avner BS, Das Gupta TK, Chakrabarty AM,. 2004. Apoptosis or growth arrest: modulation of tumor suppressor p53's specificity by bacterial redox protein Azurin. Proc. Natl. Acad. Sci. USA 101: 4770-4775. (Pubitemid 38469152)
63. Yamada T, Mehta RR, Lekmine F, Christov K, King ML, Majumdar D, Shilkaitis A, Green A, Bratescu L, Beattie CW, Das Gupta TK,. 2009. A peptide fragment of Azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol. Cancer Ther. 8: 2947-2958.